BACKGROUND:Erythromycin is generally used as a prokinetic agent for the treatment of feeding intolerance in preterm infants; however, results from previous studies significantly vary due to different medication dosages, routes of administration, and therapy durations. The effectiveness and safety of intermediate-dose oral erythromycin in very low birth weight (VLBW) infants with feeding intolerance was examined in this study. METHODS:Between November 2007 and August 2009, 45 VLBW infants with feeding intolerance, who were all at least 14 days old, were randomly allocated to a treatment group and administered 5mg/kg oral erythromycin every 6hours for 14 days (n=19). Another set of randomly selected infants was allocated to the control group, which was not administered erythromycin (n=26). RESULTS: The number of days required to achieve full enteral feeding (36.5±7.4 vs. 54.7±23.3 days, respectively; p=0.01), the duration of parenteral nutrition (p<0.05), and the time required to achieve a body weight ≥2500g (p<0.05) were significantly shorter in the erythromycin group compared with the control group. The incidence of parenteral nutrition-associated cholestasis (PNAC) and necrotizing enterocolitis (NEC) ≥ stage II after 14 days of treatment were significantly lower (p<0.05) in the erythromycin group. No significant differences were observed in terms of the incidences of sepsis, bronchopulmonary dysplasia, or retinopathy of prematurity. No adverse effects were associated with erythromycin treatment. CONCLUSIONS:Intermediate-dose oral erythromycin is effective and safe for the treatment of feeding intolerance in VLBW infants. The incidences of PNAC and ≥ stage II NEC were significant lower in the erythromycin group.
RCT Entities:
BACKGROUND:Erythromycin is generally used as a prokinetic agent for the treatment of feeding intolerance in preterm infants; however, results from previous studies significantly vary due to different medication dosages, routes of administration, and therapy durations. The effectiveness and safety of intermediate-dose oral erythromycin in very low birth weight (VLBW) infants with feeding intolerance was examined in this study. METHODS: Between November 2007 and August 2009, 45 VLBW infants with feeding intolerance, who were all at least 14 days old, were randomly allocated to a treatment group and administered 5mg/kg oral erythromycin every 6hours for 14 days (n=19). Another set of randomly selected infants was allocated to the control group, which was not administered erythromycin (n=26). RESULTS: The number of days required to achieve full enteral feeding (36.5±7.4 vs. 54.7±23.3 days, respectively; p=0.01), the duration of parenteral nutrition (p<0.05), and the time required to achieve a body weight ≥2500g (p<0.05) were significantly shorter in the erythromycin group compared with the control group. The incidence of parenteral nutrition-associated cholestasis (PNAC) and necrotizing enterocolitis (NEC) ≥ stage II after 14 days of treatment were significantly lower (p<0.05) in the erythromycin group. No significant differences were observed in terms of the incidences of sepsis, bronchopulmonary dysplasia, or retinopathy of prematurity. No adverse effects were associated with erythromycin treatment. CONCLUSIONS: Intermediate-dose oral erythromycin is effective and safe for the treatment of feeding intolerance in VLBW infants. The incidences of PNAC and ≥ stage II NEC were significant lower in the erythromycin group.
Authors: K P Economopoulos; N L Ward; C D Phillips; A Teshager; P Patel; M M Mohamed; S Hakimian; S B Cox; R Ahmed; O Moaven; K Kaliannan; S N Alam; J F Haller; A M Goldstein; A K Bhan; M S Malo; R A Hodin Journal: Diabetes Obes Metab Date: 2016-03-22 Impact factor: 6.577
Authors: Michael L Jensen; Thomas Thymann; Malene S Cilieborg; Mikkel Lykke; Lars Mølbak; Bent B Jensen; Mette Schmidt; Denise Kelly; Imke Mulder; Douglas G Burrin; Per T Sangild Journal: Am J Physiol Gastrointest Liver Physiol Date: 2013-10-24 Impact factor: 4.052
Authors: Elizabeth T Rogawski; Daniel J Westreich; Linda S Adair; Sylvia Becker-Dreps; Robert S Sandler; Rajiv Sarkar; Deepthi Kattula; Honorine D Ward; Steven Meshnick; Gagandeep Kang Journal: J Pediatr Date: 2015-09-12 Impact factor: 4.406
Authors: Jessica E Ericson; Christopher Arnold; Jomani Cheeseman; Jordan Cho; Sarah Kaneko; Ele'na Wilson; Reese H Clark; Daniel K Benjamin; Vivian Chu; P Brian Smith; Christoph P Hornik Journal: J Pediatr Gastroenterol Nutr Date: 2015-09 Impact factor: 3.288
Authors: Sourabh Dutta; Balpreet Singh; Lorraine Chessell; Jennifer Wilson; Marianne Janes; Kimberley McDonald; Shaneela Shahid; Victoria A Gardner; Aune Hjartarson; Margaret Purcha; Jennifer Watson; Chris de Boer; Barbara Gaal; Christoph Fusch Journal: Nutrients Date: 2015-01-08 Impact factor: 5.717